Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Nationally registered neuropeptides and the retrievability of their evidence base — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-017/5
Series
Evidence synthesis
Version
1.1
Published
13 May 2026
Last reviewed
13 May 2026
Next review
13 Nov 2027
Identifier
10.71829/cei.syn.17
Certainty
Very low
Cycle
2026 Q2
Review type
Methodological review
Search executed
29 Mar 2026

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
25 Feb 20260.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
24 Apr 20261.1Study reclassifiedA study previously included was reclassified as ineligible following retrieval of the full report. The quantitative synthesis was re-run without it.
Current version 1.1, ratified in the 2026 Q2 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
EPI-RU-ELDERLY09 Mar 2026No response
SELANK-RU-ANXIETY20 Feb 2026Partially supplied
SEMAX-RU-COGNITIVE23 Jan 2026Refused
SEMAX-RU-STROKE12 Jan 2026No response
THYMALIN-RU-108 Jan 2026Refused

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.